PLCG1 (phospholipase-C gamma 1), a possible alternative to amyloid-beta targeting in Alzheimer’s disease (AD), can be modulated via PLCG1-AS, a MIR-NAT with an inverted MIRb repeat. This evidence concerns the gene PLCG1 and early-onset autosomal dominant Alzheimer disease.